Company Overview and News

 
50 Technology Top Dividend Picks By Yield And Gains For April

2018-04-21 seekingalpha
Top Technology ten by broker estimated net gains, DCHIY, ASOZY, ETCMY, LNVGY, ASOZF, NOK, CAMT, QCOM, IMOS, and TIVO, averaged 19.96%, calculated 4/19/18.

 
Digital China Holdings (DCHIF) On Cooperation Between DC Holdings And GZCI - Slideshow

2017-12-27 seekingalpha
The following slide deck was published by Digital China Holdings Ltd. in conjunction with this event.

 
Top Technology Dividend Picks TiVo, Camtek, American And Magic Software Shoot At 24-88% December Gains Per Broker Targets

2017-12-27 seekingalpha
Top Technology ten by broker estimated net gains, ASOZY, ASOZF, CSYJY, IBM, ASX, XRX, MGIC, AMSWA, CAMT, & TIVO, averaged 23.36%, calculated 12/22/17.

 
Top Tech Dividend Dogs Xperi, TiVo, PCTEL, & LSI Shoot For Over 20% October Gains Per Broker Targets

2017-10-19 seekingalpha
Top Technology ten, CSCO, STX, IBM, ASX, AMSWA, QCOM, LYTS, PCTI, TIVO, & XPRI, by analyst estimated net gains, averaged 29.8%, calculated 10/13/17.

 
Week In Review: Cathay Fortune Pays $186 Million For German Diagnostic Company

2017-04-30 seekingalpha
Cathay Fortune International, a Shanghai healthcare private equity firm, will acquire Berlin's Epigenomics AG (OTCQX:EPGNY) for $186 million in cash. Epigenomics makes a blood plasma test that detects colorectal cancer. The Epi proColon diagnostic is marketed in the EU, the US and China. BioChain, a US company that is the largest shareholder of Epigenomics, owns China marketing rights to Epi proColon.

 
DC Holdings Initiates the Establishment of China Healthcare Big Data Development Co., Ltd to Construct the Healthcare Big Data Ecosystem

2017-04-28 prnewswire
HONG KONG, April 28, 2017 /PRNewswire/ -- Digital China Holdings Limited ("DC Holdings" or the "Group"; stock code: 00861.HK, 910861.TW), China's largest integrated IT service provider, is pleased to announce that the signing ceremony of China Healthcare Big Data Development Co., Ltd. (CHBDDC) was held in Beijing. DC Holdings initiated the establishment of CHBDDC. Guo Wei, Chairman of DC Holdings, and Jin Xiaotao, Deputy Director of National Health and Family Planning Commission, delivered speech at the ceremony.

 
Zebra Technologies Launches Joint Lab with JD.com and Digital China

2017-03-08 prnewswire
IoT + E-commerce Logistics Lab to drive development of next-generation logistics solutions to increase operational visibility and raise productivity

 
Twists and turns in a bitter Chinese takeover battle

2016-06-03 scmp
After losing a tussle for the leadership of China’s computer giant Legend Holding, he turned its small IT servicing department into an empire with profits of HK$900 million called Digital China Holdings, within 10 years.

 
Twists and turns in a bitter Chinese takeover battle

2016-06-03 scmp
After losing a tussle for the leadership of China’s computer giant Legend Holding, he turned its small IT servicing department into an empire with profits of HK$900 million called Digital China Holdings, within 10 years.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

22h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

23h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...